| Document |
Document Title |
|
WO/2022/152141A2 |
Provided herein are polymer conjugated lipid compounds that can be used in combination with other lipid components, such as cationic lipids, neutral lipids, and cholesterol, to form lipid nanoparticles for delivery of therapeutic agents ...
|
|
WO/2022/155614A1 |
Disclosed herein are compounds of Formula (I-A), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant ...
|
|
WO/2022/155674A1 |
The present disclosure relates to compounds, and to their pharmaceutical compositions, that inhibit dipeptidyl peptidase IV (DPP4). Hie compounds selectively promote the proliferation of alveolar type 2 cells (AEC2s) and are useful in th...
|
|
WO/2022/152282A1 |
CD22 antibodies, a preparation method therefor, and an application thereof. The CD22 antibodies have a high affinity to CD22 protein. Therefore, the CD22 antibodies can be used in the preparation of drugs for the treatment of diseases su...
|
|
WO/2022/150927A1 |
The present disclosure is generally directed to a delivery device for the automatic injection of at least two doses of a fluid into the IM site of a subject during at least two different stages of operation. The delivery device generally...
|
|
WO/2022/150621A1 |
This invention provides methods for the treatment of anemia in patients with chronic kidney disease (CKD) using vadadustat (Compound 1). Methods described herein provide alternative dosing regimens for patients having anemia. In addition...
|
|
WO/2022/150624A1 |
The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention fur...
|
|
WO/2022/150623A1 |
Provided herein are therapeutic methods comprising administering a compound (e.g., a first compound) that is a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor in combination with a compound (e.g., a second compound) that i...
|
|
WO/2022/147962A1 |
The present invention relates to the field of hemodialysis, in particular to a fat emulsion dialysate, and a preparation method therefor and the use thereof. Provided in the present invention is a fat emulsion dialysate, comprising long-...
|
|
WO/2022/147759A1 |
A gRNA molecule targeting Intron I or Intron II of β-globin gene, a synthetic method thereof, a method for constructing a repair system targeting β-globin gene mutation sites, a repair system, and a universal method to correct types of...
|
|
WO/2022/149010A1 |
The present invention relates to compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for ...
|
|
WO/2022/143675A1 |
A culture medium composition for amplifying and maintaining self-renewal capacity and differentiation potential of hematopoietic stem cells (HSCs), a cell population and an application thereof. The culture medium composition comprises a ...
|
|
WO/2022/143911A1 |
A compound of formula (I) capable of inhibiting plasmin activity and delaying fibrinolysis, and having coagulation and hemostasis activity, a pharmaceutically acceptable salt thereof, a hydrate thereof, an isomer thereof, a prodrug there...
|
|
WO/2022/143513A1 |
The present invention relates to an oral preparation comprising Erigeron breviscapus, and a preparation method therefor and an application thereof, the preparation comprising common oral dosage forms such as capsules, tablets, oral liqui...
|
|
WO/2022/145144A1 |
The present invention provides: a pharmaceutical composition for treating X-linked sideroblastic anemia, the composition comprising a demethylating agent, in particular, 5−azacitidine or a derivative thereof; and normal erythroid cells...
|
|
WO/2022/141684A1 |
Provided are a crystal form A, crystal form B, crystal form C and amorphous form of honokiol and a preparation method therefor. The method comprises: dissolving honokiol in n-heptane, standing at room temperature overnight, the precipita...
|
|
WO/2022/135421A1 |
Disclosed in the present invention are a salt form of an isoquinolinone type compound as a ROCK protein kinase inhibitor and a preparation method therefor; and use of the salt form in the preparation of a medicament for treating diseases...
|
|
WO/2022/136457A1 |
The present disclosure relates to nanobodies, such as defined by SEQ ID NOS: 1 – 54, which may be encoded by SEQ ID NOS: 55 – 110, and which are capable of specifically binding glycoprotein VI (GPVI), as well as uses thereof, which i...
|
|
WO/2022/140659A2 |
Provided herein are anti-CD47 antibodies and antigen-binding portions thereof and methods for using the same.
|
|
WO/2022/134257A1 |
A use of a compound xueshuantong capsule in preparation of a drug for reducing blood viscosity and resisting thrombus. Tests prove that: the effects of low-dose, medium-dose and high-dose groups of the compound xueshuantong capsule in re...
|
|
WO/2022/129536A1 |
The present invention relates to nicotinamide mononucleotide derivatives of Formula (I) for use in the stimulation of the expression of fetal hemoglobin. The present invention further relates to pharmaceutical compositions comprising com...
|
|
WO/2022/129308A1 |
The present invention refers to a method for treating neutropenia and/or for the activation of myelopoiesis. For that purpose, affinity reagents, preferably aptamers, have been developed in the present invention which specifically bind t...
|
|
WO/2022/126473A1 |
The present invention relates to a material and method for improving the efficiency of stem cell differentiation by means of a physical pathway, and specifically disclosed is a particle substrate material for prompting subtype differenti...
|
|
WO/2022/133263A1 |
This disclosure relates to methods for detection and measurement of anti-drug antibodies (ADAs) against Factor XI and/or Factor XIa therapeutic antibodies, e.g., in a subject being treated with said Factor XI and/or Factor XIa therapeuti...
|
|
WO/2022/133324A1 |
The present invention provides compositions comprising a recombinant AAV and one or more pharmaceutically acceptable excipients. The compositions have improved stability and shelf life as compared to other AAV compositions.
|
|
WO/2022/129490A1 |
The present invention relates to nicotinamide mononucleotide derivatives of Formula (I) for use in the treatment and/or prevention of a blood disorder, especially sickle cell disease. The present invention further relates to pharmaceutic...
|
|
WO/2022/131354A1 |
Provided is a solid formulation that has excellent stability and that is useful for treating or improving (or alleviating) dysuria regardless of the presence/absence or the severity of prostatic hyperplasia. The solid formulation inclu...
|
|
WO/2022/132765A1 |
RNA molecules comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-1538 and compositions, methods, and uses thereof.
|
|
WO/2022/132756A1 |
RNA molecules comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-1932 and compositions, methods, and uses thereof.
|
|
WO/2022/123947A1 |
Provided is a novel drug modality that at least partially overcomes the disadvantages of the conventional covalent drugs. Provided is a neutralizable covalent drug compound including a nucleic acid aptamer and a sulfonyl fluoride group l...
|
|
WO/2022/122035A1 |
Provided are a coagulation factor XIa inhibitor, a preparation method, a pharmaceutical composition and the use thereof for preventing or treating diseases related to the activity of FXIa. Specifically, provided are an amide derivative a...
|
|
WO/2022/124900A1 |
The invention relates to methods for the treatment or prevention of anaemia of inflammation comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of an i...
|
|
WO/2022/122914A1 |
The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particula...
|
|
WO/2022/125490A1 |
The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the Coagulation Factor X (F10) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an F10 gene and to methods of treat...
|
|
WO/2022/120292A1 |
The present disclosure provides a method that aims to maintain a favorable benefit-risk balance for patients with hemophilia A or B with or without inhibitors treated with fitusiran.
|
|
WO/2022/119322A1 |
The present invention provides a hemostatic composition comprising N,N,N-trimethyl chitosan and povidone iodine. Since the hemostatic composition of the present invention comprises N,N,N-trimethyl chitosan and povidone iodine at the same...
|
|
WO/2022/120291A1 |
The present disclosure provides a method that aims to maintain a favorable benefit-risk balance for patients with hemophilia A or B with or without inhibitors treated with fitusiran.
|
|
WO/2022/113371A1 |
Provided is a drug used for the treatment or prevention of cerebral hemorrhage, the drug containing, as an active ingredient, the compound of formula (I), or a pharmaceutically acceptable salt, ester or solvate thereof.
|
|
WO/2022/111561A1 |
A composition of Malus neidzwetzkyana Dieck and Prunus cerasifera Ehrhart having antithrombotic efficacy. The weight ratio of Malus neidzwetzkyana Dieck to Prunus cerasifera Ehrhart is 1: 10-10: 1. The animal experiments in zebrafish and...
|
|
WO/2022/115051A1 |
The present invention relates to a pharmaceutical composition comprising Apixaban or one of its pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient manufactured by using direct compression meth...
|
|
WO/2022/115651A1 |
Disclosed herein include methods, compositions, and kits suitable for use in preventing/treating a thromboembolic disorder, preventing/reducing formation of thrombi, and reducing/inhibiting procoagulant platelet formation. The methods co...
|
|
WO/2022/115052A1 |
The present invention relates to a pharmaceutical composition comprising Apixaban or one of its pharmaceutically acceptable salt thereof has a D90 less than 20 microns and at least one pharmaceutically acceptable excipient manufactured b...
|
|
WO/2022/114603A1 |
The present invention relates to a novel anti-C-MPL antibody and the use thereof and, more particularly, to an anti-C-MPL antibody having the effects of platelet production and increased number of platelets by means of megakaryocyte matu...
|
|
WO/2022/109684A1 |
A dosage form for oral delivery of a therapeutic agent to a subject, the dosage form comprising: (i) a lipid nanocarrier formulation, the lipid nanocarrier formulation comprising the therapeutic agent, and lipids in the form of a mesopha...
|
|
WO/2022/115502A1 |
The present disclosure relates to treatment of bleeding disorders, in particular, hemophilia A (mild, moderate or severe hemophilia) and von Willebrand disease (VWD), Type 1 or Type 2 or Type 3, using VWF targeting agents such as a PEGyl...
|
|
WO/2022/106425A1 |
The invention relates to the treatment or prevention of liver failure.
|
|
WO/2022/109161A1 |
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit...
|
|
WO/2022/109328A1 |
The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for ...
|
|
WO/2022/105725A1 |
Disclosed is a preparation method for deer velvet alcohol. The method comprises: freeze-drying fresh deer velvet, adding same into a 40-53 ° alcohol base at a 1:20-500 ratio, utilizing ultrasonic reflux extraction, and after centrifugat...
|
|
WO/2022/105877A1 |
Disclosed are a pharmaceutical composition comprising a bilobalide component and a pharmaceutically acceptable carrier or excipient, and a pharmaceutical preparation of a bilobalide component comprising a bilobalide component, a pharmace...
|
